The Trump administration announced it will not finalize a rule proposed by the Biden administration that would have allowed ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten with a federal deadline to halt off-brand products.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

Jade-Olivia Patrick, 35, from London, turned to weight-loss jabs after years of dieting. Here, she shares her life-changing ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

SaveHealth explores the historical trajectory of weight loss drugs, examining their scientific basis, regulatory battles, public reception, and what lies ahead for pharmacotherapy in obesity ...

In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...

The FDA has approved medications like Zepbound and Wegovy for weight loss, which use the same active ingredient as the ...